Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 6/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 6/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.83 |
| ▸ | SRC | P12931 | 7/20 | 0.82 |
| ▸ | FLT1 | P17948 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248489 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8135892 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130155 | 0.86 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL22532383 | 0.85 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL29390330 | 0.85 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130610 | 0.84 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8127464 | 0.83 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL30386897 | 0.82 | FGFR1 (0.69) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL31648262 | 0.82 | FGFR1 (0.76) | FGFR1FGFR2FGFR4FGFR3EGFR | |
| SCHEMBL8130201 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382583-A1 | ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| CN-117919415-A | Application of FGFR inhibitor in diabetes combined coronavirus infection | 广州国家实验室 | 2024-04-26 | — | — | CN | claimed |
| EP-3636773-B1 | N-CADHERIN AND FGFR1 AND/OR FGFR4 FOR USE IN PREDICTING THE RESPONSE OF PATIENTS TO A LUNG CANCER TREATMENT AND METHOD AND KIT BASED ON SAID USE | FUNDACION DE INVESTIG HOSPITAL 12 DE OCTUBRE (ES) | 2023-08-23 | — | — | EP | claimed |
| US-20230220334-A1 | DIFFERENTIATION OF TROPHECTODERM LINEAGE CELLS FROM PLURIPOTENT STEM CELLS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2023-07-13 | — | — | US | claimed |
| US-20220364060-A1 | ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS | WASHINGTON UNIVERSITY | 2022-11-17 | — | — | US | claimed |
| US-11408038-B2 | N-cadherin and FGFR1 and/or FGFR4 for use in predicting the response of patients to a lung cancer treatment and method and kit based on said use | FUNDACIÓN DE INVESTIGACIÓN HOSPITAL 12 DE OCTUBRE | 2022-08-09 | — | — | US | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075674-A | Application of reagent for inhibiting NNMT binding FGFR1 in tumor prevention and treatment | — | 2026-05-26 | — | — | CN | disclosed |
| US-12636370-B2 | Combination therapy for treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| CN-108473962-B | Reproducible differentiation method of clinical grade retinal pigment epithelial cells | (由卫生与公众服务部部长代表的)美利坚合众国 | 2022-04-26 | — | — | CN | disclosed |
| CN-114286816-A | Difluoro-halogenated allylamine sulfone derivative inhibitor of lysyl oxidase, preparation method and application thereof | 法玛西斯有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-108379591-B | Synthesis of immune agonist targeting compound and application thereof | 深圳大学 | 2022-03-29 | — | — | CN | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3954436-A1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-20220033770-A1 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | FUJIFILM Cellular Dynamics, Inc. (US) | 2022-02-03 | — | — | US | disclosed |
| CN-113993528-A | Method for producing living body-like tissue structure | 千纸鹤治疗公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636370-B2 | Combination therapy for treatment of cancer | RB1, MDM2, PHKB | FGFR1 2126/4885FGFR2 1825/4885FGFR4 3521/4885 |
| US-20260103678-A1 | BILAYER OF RETINAL PIGMENTED EPITHELIUM AND PHOTORECEPTORS AND USE THEREOF | PAX2, ZP1, ALDH1A2 | FGFR1 712/4885FGFR2 1293/4885FGFR4 1109/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | FGFR1 1/4885FGFR2 4/4885FGFR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.